Bristol-Myers Squibb revenue and financials
$59.59Change from previous close: +1.33%Absolute change: +$0.78
In the fiscal year ended December 2025, Bristol-Myers Squibb reported revenue of $48.19B (−0.22% year over year). Net income was $7.05B, a net margin of 14.6%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- −0.22%
- 2025 vs 2024
- Net margin
- 14.6%
- 2024: -18.5%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 14,156 | 15,190 | 13,860 | 13,066 | 16,207 | 14,052 | 8,210 | 7,066 | 5,275 | 3,058 |
| Depreciation and amortization | 4,011 | 9,600 | 9,760 | 10,276 | 10,686 | 10,380 | 1,746 | 637 | 789 | 382 |
| Capital expenditure | -1,311 | -1,248 | -1,209 | -1,118 | -973 | -753 | -836 | -951 | -1,055 | -1,215 |
| Investing cash flow | -4,132 | -21,352 | -2,295 | -1,062 | -538 | — | — | — | — | — |
| Financing cash flow | -10,348 | 5,127 | -9,416 | -16,962 | -16,224 | — | — | — | — | — |
| Dividends paid | -5,045 | -4,863 | -4,744 | -4,634 | -4,396 | -4,075 | -2,679 | -2,613 | -2,577 | -2,547 |
| Share repurchases | 0.0 | 0.0 | -5,155 | -8,001 | -6,287 | -1,546 | -7,300 | -320 | -2,469 | -231 |
| Debt issued | 5,765 | 15,969 | 4,455 | 6,120 | — | — | — | — | — | — |
| Debt repaid | -10,940 | -5,873 | -3,999 | -11,431 | -6,182 | — | — | — | — | — |
| Effect of exchange rates | 195 | -137 | 45.0 | -33.0 | -102 | — | — | — | — | — |
| Net change in cash | -129 | -1,172 | 2,194 | -4,991 | -657 | — | — | — | — | — |
| Free cash flow | 12,845 | 13,942 | 12,651 | 11,948 | 15,234 | — | — | — | — | — |
| Levered free cash flow | 11,147 | 16,890 | 13,602 | 13,341 | 12,786 | — | — | — | — | — |